Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database

Abstract

Background : Balloon-expandable pulmonary valves are usually not suitable for dilated native outflow tracts. Methods : Indian Venus P-valve registry was retrospectively analyzed for efficacy, complications, and midterm outcomes. Straight valve was used in prestented conduits in patients with right ventricular pressure above two-thirds systemic pressure and/or right ventricular dysfunction. Flared valve 1–4 mm larger than balloon waist was used in native outflow in symptomatic patients, large ventricular volumes, and ventricular dysfunction. Objectives : A self-expanding porcine pericardial Venus P-valve is available in straight and flared designs.. Results : Twenty-nine patients were included. Straight valve was successful in all seven conduits, reducing gradients significantly, including one patient with left pulmonary artery (LPA) stent. Flared valve was successfully implanted in 20 out of 22 native outflow tracts. Sharp edges of the older design contributed to two failures. Complications included two migrations with one needing surgery, endocarditis in one, insignificant wire-frame fractures in three, and groin vascular complication in one patient. There were no deaths or valve-related reinterventions at a mean follow-up of 47.8 ± 24.5 months (1–85 months). Modifications of technique succeeded in three patients with narrow LPA. There was significant improvement in symptoms, right ventricular volume, and pulmonary regurgitant fraction. Conclusion : Straight and flared Venus P-valves are safe and effective in appropriate outflow tracts. Straight valve is an alternative to balloon-expandable valves in stenosed conduits. Flared valve is suitable for large outflows up to 34 mm, including patients with LPA stenosis. Recent design modifications may correct previous technical failures. Studies should focus on durability and late complications.

First hybrid implantations of novel Salus-Valves in patients with severe pulmonary regurgitation: A case series

“…Many patients were not able to receive these valves due to large RVOT diameters and irregular postoperative RVOT anatomies ( 4 , 12 ). Newer PPVI systems such as Venus P-valve (Venus MedTech, Hangzhou, China) and Myval valve (Meril LifeSciences Pvt., Ltd., India) have been used to treat these patients ( 13 – 15 ). Until now, the Venus P-valve has the largest diameter of all PPVI systems.…”

CMR and Percutaneous Treatment of Pulmonary Regurgitation: Outreach the Search for the Best Candidate

“…It is available for 20 mm, 23 mm, 26 mm, and 29 mm valve sizes and can be used up to a 30 mm RVOT diameter, including pre-stenting [ 22 ]. The PULSTA valve (TaeWoong Medical Co., Gimpo-si, Republic of Korea) is anatomically suitable for RVOT diameters up to 28 mm, while the Venous p -valve (Venus MedTech, Hangzhou, China) can be used for large RVOTs up to 36 mm in diameter [ 23 , 24 , 25 ]. An asymmetric self-expanding stent with larger proximal and distal ends characterizes the Harmony valve (Medtronic), which already has FDA approval and could be used in different RVOT types with very large diameters (≥40 mm) [ 26 ].…”

Holography-guided procedural planning for modifying Venus P-valve implantation technique in patients with left pulmonary artery stents: a case-series

“…Self-expanding systems provide valve competence despite significant dilatation of the native RVOT ( 8 ). For this reason, self-expandable valves have been developed and recently tested internationally and in Europe ( 14 ). The Venus P -valve™ (Venus Medtech, Hangzhou, China) is a self-expandable bioprosthetic valve that was granted CE-Mark approval under EU MDR (2017/745) for treating patients with pulmonary regurgitation (PR) in the setting of native outflow tracts on April 8, 2022.…”

“…The Venus P -valve™ (Venus Medtech, Hangzhou, China) is a self-expandable bioprosthetic valve that was granted CE-Mark approval under EU MDR (2017/745) for treating patients with pulmonary regurgitation (PR) in the setting of native outflow tracts on April 8, 2022. It is available in two different designs; the straight design has been used for conduits, and the flared one is more appropriate for the treatment of the native RVOT previously repaired with transannular patches ( 14 , 15 ). The flared Venus P -valve consists of a self-expanding nitinol frame and a tri-leaflet valve sutured to a scalloped skirt ( Figure 2 ).…”

“…The transcatheter implantation of the Venus P -valve involves the opening of the distal valve flare into one of the PA branches, usually the LPA but also the right pulmonary artery (RPA), to guarantee valve stability during and after the device deployment ( 15 ). For this reason, the presence of a previous LPA stent has been reported as a relative contraindication to Venus P -valve implantation ( 14 ).…”